From the Division of Cancer Medicine, Department of Melanoma Medical Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX.
Cancer J. 2024;30(2):102-107. doi: 10.1097/PPO.0000000000000711.
Development of brain metastasis is one of the most serious complications of advanced melanoma, carrying a significant burden of morbidity and mortality. Although advances in local treatment modalities such as stereotactic radiosurgery and breakthrough systemic therapies including immunotherapy and targeted therapies have improved the outcomes of patients with metastatic melanoma, management of patients with melanoma brain metastases (MBMs) remains challenging. Notably, patients with MBMs have historically been excluded from clinical trials, limiting insights into their specific treatment responses. Encouragingly, a growing body of evidence shows the potential of systemic therapies to yield durable intracranial responses in these patients, highlighting the need for inclusion of patients with MBMs in future clinical trials. This is pivotal for expediting the advancement of novel therapies tailored to this distinct patient population. In this review, we will highlight the evolving landscape of MBM management, focusing on local and systemic treatment strategies.
脑转移的发展是晚期黑色素瘤最严重的并发症之一,给患者带来了严重的发病率和死亡率负担。尽管立体定向放射外科等局部治疗方法的进展以及免疫治疗和靶向治疗等突破性全身治疗方法改善了转移性黑色素瘤患者的预后,但黑色素瘤脑转移(MBM)患者的管理仍然具有挑战性。值得注意的是,MBM 患者历来被排除在临床试验之外,限制了对其特定治疗反应的了解。令人鼓舞的是,越来越多的证据表明全身治疗有潜力为这些患者带来持久的颅内反应,这凸显了未来临床试验中纳入 MBM 患者的必要性。这对于加快为这一独特患者群体量身定制的新型疗法的发展至关重要。在这篇综述中,我们将重点介绍 MBM 管理的不断发展的格局,包括局部和全身治疗策略。